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A B S T R A C T
Carbamazepine is used to control seizures. Its common side effects are sleep disorders, anorexia, nausea,
vomiting, polydipsia, irritability, ataxia, and diplopia. Involvement of the immune system is rare, and few
cases of decreased immunoglobulin levels have been reported. We describe a patient with low
immunoglobulin levels due to carbamazepine use who presented with recurrent urinary tract infection.
Intravenous immunoglobulin was administered, and immunoglobulin levels increased to safer levels
after discontinuation of carbamazepine. Previous reports describe severe infection after carbamazepine-
induced hypogammaglobulinemia. Therefore, in patients using antiepileptics, particularly carbamaze-
pine, serum immunoglobulin levels should be checked in those with recurrent infections.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Carbamazepine is used to control certain types of seizures. The
most commonly encountered side effects include sleep disorders,
anorexia, nausea, vomiting, polydipsia, irritability, ataxia, and
diplopia.1 Involvement of the immune system, manifesting as
dermatitis, eosinophilia, leukopenia, lymphadenopathy, and
splenomegaly, has also been reported.1,2
Decreased immunoglobulin levels after carbamazepine use is
rare, and few cases have been reported.3–7 We report on a patient
with transiently low immunoglobulin levels due to carbamazepine
use who presented with recurrent urinary tract infection.
2. Case report
A 37-year-old male was ﬁrst admitted with Jacksonian seizures
involving the left side of his body and loss of consciousness. He was
found to have a right parietal mass and underwent surgery for a
subtotal removal of the mass. The histology of the mass was
consistent with oligodendroglioma (World Health Organization
classiﬁcation, Grade II). He was prescribed carbamazepine,
lamotrigine, and clonazepam. He continued to have some hemi-
dysesthesia, and his seizures increased. Because his seizures were
intractable, right then left sided stereotactic thalamotomies were* Corresponding author at: Istanbul University, Cerrahpasa Medical School,
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day) was continued. Within 6 years he required a ventriculo-atrial
shunt operation and revision operations for hydrocephalus. Blood
carbamazepine levels were within normal limits on several
occasions. A physical therapy program was initiated. He did not
need a urinary catheter.
In the 6 months prior to presentation the patient developed 3
episodes of urinary tract infections, all associated with systemic
signs and symptoms (fever, ﬂank pain, leukocytosis and increased
C-reactive protein levels) The infections were due to Escherichia
coli (treated with ceftriaxone), Klebsiella sp. (treated with
meropenem), and Pseudomonas aeruginosa (partially sensitive to
meropenem and amikacin and treated with a combination of these
drugs). Concurrently, a pink-red maculo-papular rash on the face
and trunk was noted, with the lesions varying in size from 2 mm to
10 mm. The platelet counts ranged from 100,000/mm3 to 150,000/
mm3. An ultrasound scan of the renal tract was negative. His
complete blood count and leukocyte differential (55% neutrophils,
40% lymphocytes, 3% eosinophils, and 2% monocytes) were normal
except for a slightly low platelet count (135,000/mm3). He had not
been given any drug with known immunosuppressive properties.
The immunoglobulin assay revealed low IgG and IgM levels: IgG
275 mg/dL (normal: 884–1912 mg/dL), IgM 31 mg/dL (n: 50–
196 mg/dL), IgA 94 mg/dL (n: 68–423 mg/dL). Ig subclasses were
also determined: IgG1 132 mg/dL, IgG2 100 mg/dL, and IgG3 3 mg/
dL. Urinalysis revealed leukocytes, and urine culture yielded P.
aeruginosa, which was resistant to all the antibiotics tested. The C-
reactive protein level was 30 times higher than normal.
Although the carbamazepine level was 7 mcg/mL (normal
range: 4–12 mcg/mL), it was discontinued. The rash disappearedvier Ltd. All rights reserved.
Fig. 1. Immunoglobulin G (solid line) and M (dashed line) levels after discontinuation of carbamazepine. Black arrows show intravenous immunoglobulin administrations.
Unit for both IgG and IgM is mg/dL.
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10 days. The urinary tract infection was successfully treated with
colistin. The patient was given intravenous immunoglobulin
(400 mg/kg, 32 g); because the immunoglobulin levels remained
low, it was administered three more times. Four months after
discontinuation no more immunoglobulin was needed (Fig. 1).
During a follow-up of 1 year, the patient was doing well, without
any rash or infection.
3. Discussion
Transient hypogammaglobulinemia has been associated in
reports with the administration of carbamazepine as well as
phenytoin.8 Depression of one or more parameters of cellular and/
or humoral immune responses was observed in 49% of general
hospital patients treated with carbamazepine and 60% of patients
treated with phenytoin.9 Despite this, these ﬁndings may not
translate into clinical complications (for example recurrent
infections). Even among patients admitted with recurrent infec-
tions, carbamazepine-induced immune deﬁciencies are considered
rare.3–7,10
The mechanisms underlying hypogammaglobulinemia induced
by carbamazepine are not well understood. Marcoli et al.11
reported lymphocyte and immunoglobulin abnormalities in 65
patients undergoing long-term monotherapy (at least 3 months)
with phenytoin, carbamazepine, or phenobarbital. A signiﬁcant
decrease of OKT4+ cells was observed with all drugs, while other
lymphocyte subpopulations were differently affected depending
on the drug used; they concluded that these drugs produce
immunosuppressant effects through a complex action involving
more than one lymphocyte subpopulation. Gilhus et al. found
reductions of IgG2, IgA, and IgM in epileptic patients treated with
carbamazepine but no signiﬁcant changes in lymphocyte numbers
or in vitro responses to mitogens.12–14 Basaran et al.15 have
investigated the effects of phenytoin or carbamazepine on humoral
and cellular immunity and found that B lymphocyte numbers were
unaffected by carbamazepine but IgM concentrations were
signiﬁcantly low; this effect was most pronounced in the ﬁrst year.
Garcia Rodriguez et al.16 described a patient with rash, fever,
absence of B lymphocytes, and profound hypogammaglobulinemia:
these changes returned to normal when the drug was discontinued.
Spickett et al.10 reported a case of symptomatic hypogammaglo-
bulinemia with absent B lymphocytes and agranulocytosis inassociation with carbamazepine treatment. They suggested that
the regular association of anticonvulsant treatment with hypogam-
maglobulinemia may be due to the sharing of key surface molecules
between the lymphoid and nervous systems. Based on these reports,
carbamazepine-induced immune disorders can be classiﬁed into
three groups: an absence of B cells, extensive impairment of the
synthesis of Igs in B cells, and a class-switch disorder of Igs in B
cells.3,4,10,16,17 Our case seems to belong to the second group. Side
effects on immune functions do not seem to depend on the dose or
on the serum concentration, or on the duration of treatment.3
Our patient revealed slight thrombocytopenia. Carbamazepine-
induced thrombocytopenia is uncommon. It most often develops
2 weeks after the initiation of the drug and improves within
1 week after discontinuation.18 Although the exact mechanism is
unknown, the detection of carbamazepine-dependent antibodies
suggested an immune mechanism.19,20
The immunosuppression attributed to anticonvulsants is
generally reversible following drug withdrawal, and this was
the case with our patient. Although the rash disappeared within a
few days, immunoglobulin levels increased over a period of
months and needed to be replaced. The recovery of immunoglob-
ulin levels after antiepileptic use usually occurs 4 months to
6 years after the discontinuation of the drug.21 Because the exact
mechanism of low immune globulin levels during carbamazepine
use is not known, it is difﬁcult to speculate why the recovery period
is so long. It is possible that each of the proposed mechanisms (an
absence of B cells, extensive impairment of the synthesis of Igs in B
cells, and a class-switch disorder of Igs in B cells) may need months
to recover. IgG values higher than 500 mg/dL are considered to be
protective in patients with hypogammaglobulinemia for the
purpose of reducing the recurrence of infections.22,23 Accordingly
we replaced immunoglobulins until IgG values were higher than
500 mg/dL.
Immunoglobulins play an important role in adaptive immunity;
low levels of immunoglobulins are well known to be associated
with an increased risk of infections.23 The type of infection
generally depends on which immunoglobulin species is deﬁcient.
Sustained very low levels of IgA, IgG, and IgM are associated with
signiﬁcantly increased risk of infections, especially respiratory
tract infections of bacterial origin. The threshold level of IgG that is
associated with an increased risk of infection is not known. The
general consensus is that intravenous Ig treatment should aim to
achieve a serum IgG level of >500 mg/dL.23 Although transient
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be associated with an increased risk of infection, the presence of
certain comorbidities and failure to treat the infection, as in our
case, may require the replenishment of IgG.
The disorders observed after carbamazepine-induced hypo-
gammaglobulinemia may be severe: case reports describe
bronchiolitis obliterans organizing pneumonia (BOOP),5 acute
interstitial pneumonia,24 herpes encephalitis,6 recurrent sinusitis,3
reactivation of human herpesvirus 6 infection,7 and visceral
leishmaniasis.4 BOOP is suggested to be a side effect of the drug
or a sequela of drug-induced lupus25 or repeated respiratory
infections caused by carbamazepine-induced hypogammaglobu-
linemia.5
The presence of rash and thrombocytopenia raised the
suspicion of a drug-related event in our case. However, these
ﬁndings are not always associated. Therefore, in patients using
antiepileptics, especially carbamazepine, serum immunoglobulins
levels should be checked in those with recurrent infections.
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